Foamix Pharmaceuticals Ltd. (FOMX) financial statements (2020 and earlier)

Company profile

Business Address 2 HOLZMAN ST.
REHOVOT, 76704
State of Incorp.
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:729916
Cash and cash equivalents442816
Short-term investments287151
Other undisclosed cash, cash equivalents, and short-term investments  (51)
Restricted cash and investments111
Receivables011
Inventory, net of allowances, customer advances and progress billings1  
Inventory1  
Derivative instruments and hedges, assets (0)0
Other undisclosed current assets2152
Total current assets:7610170
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment322
Long-term investments and receivables 09
Long-term investments 09
Restricted cash and investments 00
Other noncurrent assets000
Total noncurrent assets:5311
TOTAL ASSETS:8110480
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2844
Accounts payable1900
Accrued liabilities302
Employee-related liabilities532
Debt1  
Deferred revenue and credits0
Other undisclosed current liabilities066
Total current liabilities:291010
Noncurrent Liabilities
Long-term debt and lease obligation33  
Long-term debt, excluding current maturities33  
Operating lease, liability1
Other undisclosed noncurrent liabilities111
Total noncurrent liabilities:3411
Total liabilities:641212
Stockholders' equity
Stockholders' equity attributable to parent189269
Common stock322
Additional paid in capital325305208
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(311)(215)(141)
Total stockholders' equity:189269
TOTAL LIABILITIES AND EQUITY:8110480

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenues044
Revenue, net4
Net investment income10 
Cost of revenue  (0)
Gross profit:044
Operating expenses(96)(78)(69)
Operating loss:(96)(75)(66)
Interest and debt expense(1)  
Loss from continuing operations before equity method investments, income taxes:(97)(75)(66)
Other undisclosed income from continuing operations before income taxes111
Loss from continuing operations before income taxes:(95)(74)(65)
Income tax expense (benefit)0(0)(1)
Net loss available to common stockholders, diluted:(95)(74)(66)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(95)(74)(66)
Comprehensive loss:(95)(74)(66)
Other undisclosed comprehensive income, net of tax, attributable to parent000
Comprehensive loss, net of tax, attributable to parent:(95)(74)(66)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: